
zzso an oral inhibitor of vascular zzso growth factor zzso zzso zzso growth factor zzso zzso and zzso growth factor zzso zzso was administered in fed conditions to 24 patients with advanced solid cancer at 100, 200 and 300 zzso zzso zzso escalation was discontinued because the maximum tolerated dose was defined at 400 zzso zzso in a zzso zzso The drug was generally well tolerated although two patients presented possibly drug-related zzso zzso zzso zzso and zzso zzso had a zzso zzso profile characterized by zzso and zzso decreasing from day 1 to day 28 in all patients at all tested zzso a lower apparent zzso on day 28 compared to day 1; and a significant zzso increase of the urinary zzso These findings are in agreement with the presence of zzso zzso and zzso zzso The peculiar zzso and zzso protein binding discouraged further clinical development of oral zzso in zzso 

